Arana Therapeutics Successfully Completes Phase II Psoriasis Study; ART621 Meets Primary Endpoint

Published: Mar 09, 2009

Monday, 09 March 2009 Sydney, Australia -- Arana Therapeutics Limited (ASX: AAH) today announced positive results from its Phase II trial of ART621 in patients with stable plaque psoriasis. The primary endpoint was met with repeat doses of ART621 being well tolerated and exhibiting a safety profile consistent with anti-TNF activity, the method of administration and the underlying study population. Arana will continue clinical development of ART621with two ongoing Phase II trials for rheumatoid arthritis (RA) in combination with methotrexate.

Secondary findings from the study provided insight into the efficacy, immunogenicity and pharmacokinetics of ART621. While the study was not designed to demonstrate efficacy, evidence of some anti-TNF activity was seen. A total of four subjects in the ART621 group achieved a 50% reduction in Psoriasis Area and Severity Index (PASI) score at week 12 compared to zero in the placebo group. One of these ART621 subjects also achieved a 90% PASI reduction.

No human anti-ART621 antibody responses were detected for up to four weeks after the last injection, suggesting inherently low immunogenicity of the drug. Consistent with prior Phase 1 data, ART621 exhibited a half life of approximately 14 days, which compares favourably to market leading anti-TNF products.

“We are pleased with the outcome of our Phase II study which has provided us with the confidence to continue clinical development of ART621. The data indicate that ART621 possesses anti-TNF activity, was well tolerated and has a competitive half life. Importantly we did not see any antibody responses against ART621 and this may be an important differentiator commercially, as other anti-TNF products may have their efficacy reduced by such responses” said Steffen Nock, Acting Chief Executive Officer.

“ART621 is now at an exciting stage with an open IND, encouraging clinical data, scale up of manufacturing progressing well and ongoing clinical trials in RA.”

Further detail on the results and study design are provided in the Appendix (and / or on our website

ART 621-201 Trial Details

The study known as ART621-201 was designed to evaluate the safety, efficacy and pharmacokinetics of 3 dose levels of ART621 using a randomised, double-blind, placebo-controlled design in subjects with plaque psoriasis. The primary objective was to evaluate the safety and tolerability of subcutaneous injections of ART621 given every 2 weeks for 6 doses as assessed by adverse events and clinical laboratory data. Assessments of efficacy included the Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), photographs and the Dermatology Life Quality Index (DLQI).

Each subject completed a 2-4 week screening period, followed by a 12 week treatment period and then a 4 week follow up. Each subject received their designated dose of study medication on 6 occasions over the 12 week treatment period.

The study was conducted to ICH GCP standard at two Australian study centres – Nucleus Network in Melbourne and CMAX in Adelaide.

For further information:

Contact information:

Company: Investor & Media Relations:

Steffen Nock Paul Dekkers Acting CEO Buchan Consulting Arana Therapeutics T: + 61 2 9237 2800 T: + 61 2 8061 9900 Mobile: 0418 218 722 E: E:

About Arana Therapeutics:

Arana Therapeutics (ASX: AAH) is a biopharmaceutical company focused on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.

Arana Therapeutics’ innovative engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline. Arana has a significant track record of commercialising its technologies and has collaborations with GlaxoSmithKline (GSK), CSL, Kyowa Hakko Kirin (KHK), and licensing arrangements with Centocor (J&J) and Abbott Laboratories.

For further information:

Back to news